Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioMarin Pharmaceutical Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on rare genetic diseases. Recent 8-K reports disclose operating and financial results, material events, material agreements, capital-structure matters and clinical or regulatory updates tied to products and programs such as VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
The company’s proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards and other governance disclosures. Filing records also cover common stock listing details, financing activities, acquisition-related disclosures and business updates affecting BioMarin’s commercial rare-disease portfolio and development pipeline.
Q2 2025 highlights: BioMarin (BMRN) generated total revenue of $825.4 million, up 16% YoY, led by VOXZOGO (+20%) and VIMIZIM (+21%). Cost of sales grew in line with volume, while R&D (-12%) and SG&A (-12%) fell, expanding operating income to $276.9 million versus $120.5 million last year. Net income more than doubled to $240.5 million; diluted EPS rose to $1.23 from $0.55.
Margins & cash: Gross margin remained about 81.5%; operating margin widened to 33.5% (19.0% prior year). Operating cash flow climbed 117% to $359.7 million, lifting cash and equivalents to $1.21 billion. Convertible debt is unchanged at $600 million, leaving net leverage very low. Retained earnings swung to a $232 million surplus from a $(195) million deficit at year-end.
Product mix Q2 2025:
- VOXZOGO $221.4 m
- VIMIZIM $215.4 m
- NAGLAZYME $128.9 m
- PALYNZIQ $105.9 m
- ALDURAZYME $56.4 m
- BRINEURA $48.7 m
- KUVAN $27.0 m (generic erosion)
- ROCTAVIAN $9.2 m
Balance-sheet notes: Inventory increased 9% to $1.34 billion; AOCI turned to a $(44.6) million loss mainly from FX hedge marks. Three customers represent 38% of net product revenue.
Events after quarter-end: Closed $270 million all-cash acquisition of Inozyme Pharma, adding late-stage enzyme therapy BMN-401; assessing impact of newly enacted U.S. OBBB tax law.